| | |

Risk for Malnutrition Among Older Mesothelioma Patients

risk for malnutrition among older mesothelioma patients

A new study out of Brazil suggests that many older mesothelioma patients may be at risk for malnutrition and the problems that go with it. 

The study included more than 4,500 Brazliian cancer patients from 45 hospitals. They were evaluated for their nutritional status, nutritional risk, and nutrition-related symptoms.

Among the 25% of cancer patients over 65, more than half faced a moderate to severe risk for malnutrition. The findings suggest it is a problem hospitals should identify and address early for the best mesothelioma treatment outcomes

Mesothelioma and Nutritional Status

As with other types of cancer, nutrition has an affect on the treatment of people with mesothelioma. 

An Australian study of pleural mesothelioma patients earlier this year found that patients with lower muscle mass or those who were malnourished faced a much poorer quality of life. In that study, 38 percent of the mesothelioma patients were at risk for malnutrition.

Another study in the journal Nutrition and Cancer showed that patients with the best nutritional status often have longer mesothelioma survival. Nutritional status measures the state of a person’s health in terms of certain lab values. 

A nutritional status score provides a snapshot of how well a patient’s cells are being nourished. The theory is that healthy cells are more likely to be able to fight off mesothelioma.

A 2017 mesothelioma study also found a higher risk for malnutrition among elderly patients.  That study showed that poorly nourished patients tended to have a worse mesothelioma prognosis.

Measuring Risk for Malnutrition Among Cancer Patients

The Brazilian study did not focus specifically on malignant mesothelioma. It included 4,783 patients with various types of cancer. Patients were admitted to 45 public hospitals. Each of them was assessed to see where they stood nutritionally.

Over a quarter of the participants were seniors over 65. Fifty-five percent of these cancer patients had moderate or severe risk for malnutrition. The risk dropped to 36 percent among people between 51 and 64. Younger patients did not seem to have the same problems.

The primary reasons these patients gave for their poor nutritional status were lack of appetite and dry mouth. Some patients also said they had swallowing difficulties. The researchers conclude that this kind of assessment should become a routine part of cancer care for hospitalized patients.

“Nutritional screening and assessment should be performed immediately after hospitalization to enable early diagnosis and multidisciplinary or interdisciplinary intervention(s),” they write.

Cancer experts recommend a diet rich in fruits and vegetables and lean proteins to avoid the risk for malnutrition during mesothelioma treatment. Specialists in cancer nutrition can often help mesothelioma patients cope with problems like poor appetite and nausea.

Source:

De Pinho, NB, et al, “High prevalence of malnutrition and nutrition impact symptoms in older patients with cancer: Results of a Brazilian multicenter study”, September 9, 2019, Cancer, Epub ahead of print, https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32437

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…